S/N Unknown   PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	DAWSON et al.	Examiner:	Unknown
Serial No.:	Unknown	Group Art Unit:	Unknown
Filed:	July 21, 2006	Docket No.:	11123.0108USWO
Title:	PHARMACEUTICAL FORMULATIONS COMPRISING METFORMIN AND A FIBRATE, AND PROCESSES FOR OBTAINING THEM		

CERTIFICATE UNDER 37 CFR 1.10:
"Express Mail" mailing label number: EV 841294615 US
Date of Deposit: July 21, 2006

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to
Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop: PCT, Commissioner for
Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

By:
Name: John

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the

enclosed Form 1449 are brought to the attention of the Examiner. Enclosed for the Examiner's

information is a copy of the International Search Report. At least some of the references were

cited in an International Search Report mailed June 15, 2005.

This statement should be considered because it is submitted within three months of the

filing date of the above-identified application, which is not an application under 37 C.F.R.

§ 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form

1449.

A copy of any foreign patent document or "Other Document" listed on the Form 1449 is

enclosed, in accordance with 37 C.F.R. §1.98(a)(2). Because this application was filed after June

30, 2003, copies of the U.S. Patents and U.S. patent publications listed on the enclosed Form

1449 are not provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

> **23552**
> PATENT TRADEMARK OFFICE

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, MN 55402-0903
(612)332.5300

Dated: 7/21/06

By: _____
Gregory A. Sebald
Reg. No.: 33,280

GAS/ncb

Date Mailed: July 21, 2006

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11123.0108USWO	Application Number: Unknown
	Applicant: DAWSON et al.	
	Filing Date: July 21, 2006	Group Art Unit: Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/D.S./	6,074,670	06-2000	Stamm et al.			
/D.S./	4,895,726	01-1990	Curtet et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
/D.S./	99/40904	08-1999	WIPO				
/D.S./	1 424 070 AI	06-2004	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	De Silva et al. "Metformin and Clofibrate in Maturity Onset Diabetes Mellitus : Advantages of Combined Treatment" Diabetic & Metabolisme (Paris) 1979, 5, p. 223-229.

23552
PATENT TRADEMARK OFFICE

EXAMINER /Danielle Sullivan/	DATE CONSIDERED 10/01/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)   Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE